“Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL”

Has just been published! Dr Gavin Cull,  clinical and laboratory haematologist at Sir Charles Gairdner Hospital (SCGH)  is the Principal Investigator of the Clinical Trial at SCGH, and also a co-author of the Publication, which uses Zanubrutinib.

Dr Cull (below) provided BCRWA with a quote about this exciting study:

“This trial shows that zanubrutinib, a tablet taken twice daily, is very active in chronic lymphocytic leukaemia. The response rates were very high and the CLL came under good control in nearly all the patients. The good news for patients is that zanubrutinib was well tolerated with very few having to stop the tablets due to side-effects. While longer follow-up is needed, most patients remain on zanubrutinib with their CLL under very good control”

The publication can be found here:
http://www.bloodjournal.org/content/early/2019/07/24/blood.2019001160?sso-checked=true 

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

By Dr Allison Barraclough, who trained and worked in WA before recently relocating to Melbourne, and several collaborating co-authors (including four from Western Australia), which looked into gene-expression profiling and prognosis for patients with stage I/II Diffuse Large B-Cell Lymphoma (DLBCL).

211 patients were identified for this retrospective study across Sir Charles Gairdner Hospital, Hollywood Private Hospital, Princess Alexandra Hospital, British Columbia Centre for Lymphoid Cancer, Aalborg University Hospital, and Nottingham University Hospital.

Key points of note:

• In early-stage DLBCL, COO and DE/DH [gene expression] status may not confer an inferior prognosis.
• Stage I/II DLBCL has an excellent outcome when treated with R-CHOP–like therapy ± radiation, with 4-year Progression Free Survival and Overall Survival rates of 85% and 88%.

The full article can be viewed here: http://www.bloodadvances.org/content/3/13/2013?sso-checked=true 

In collaboration with Lymphoma Australia, Associate Professor Chan Cheah explains how to access Clinical Trials in WA

Blood Cancer Research WA have an alliance with three Health Sites: Sir Charles Gairdner Hospital, LINEAR & Hollywood Private Hospital. Across these Sites there is a portfolio of clinical trials. Information and contact details for each trial can be found at: https://www.bloodcancerwa.org.au/trials/ 

Hodgkin’s Lymphoma Fact Sheet

By Lymphoma Australia

“Lymphoma is the 5th most common cancer in Australia and the most common blood cancer.
There are two main categories of lymphoma: Hodgkin Lymphoma and non-Hodgkin Lymphoma (of which and there are over 60 different subtypes). Lymphoma is a cancer of the white blood cells called lymphocytes. When lymphocytes gain DNA mutations they divide and grow uncontrollably, resulting in lymphoma. Lymphoma cells are often found in lymph nodes, the spleen, the bone marrow or blood, but can affect almost any organ or tissue…/..

HL is an aggressive (or fast growing) lymphoma. Usually the first sign of HL is a painless, rapidly growing lump in the neck, arm pit or groin. The swelling may be painful if the lymph node is pressing on a sensitive area (nerve or blood vessel). Other common symptoms may include sweats, fever, unexplained weight loss, generalised all over body itch and people may also notice fatigue, loss of appetite, shortness of breath or pain”.

“Clinical trials are essential in identifying effective medicines and determining optimal doses of these medicines for people diagnosed with lymphoma”.

The above abstracts are from our Sponsor: Lymphoma Australia
Please visit their website to access easy-to-read fact sheets developed by people with Lymphoma, their carer’s, families & friends:
https://engonetlymaus.blob.core.windows.net/assets/uploads/files/Fact%20Sheets/LYA084_HL_FactSheet_FA(web).pdf

CPI-818-001 is a first-in-human study for patients with relapsed or refractory
T-Cell Lymphoma

Principal Investigator of this study, and Clinical Haematology Consultant, Dr Dejan Radeski (below), provides us with an overview of this exciting trial:

“T-cells are very important members of the immune system and their three main roles are to help other parts of the immune system to do their job, to directly kill infections/cancers in the body and also to regulate the immune system so as to not attack itself. Sadly, T-cells can be develop cancer themselves and they can be difficult to treat. CPI-818 is a new tablet treatment which targets the internal machinery of the cancerous T-cell. In Western Australia the first patients in the world are being treated with this medicine and people who are eligible for this clinical trial are those with T-cell lymphoma which has persisted or come back after two different combinations of chemotherapy”.

For further information on this study, and for contact details for the Trial Coordinators at LINEAR,  please visit our website: https://www.bloodcancerwa.org.au/trial/cpi-818-001/

Lymphoma Australia  is a proud supporter of the WA Lymphoma Centre of Research Excellence and Blood Cancer Research WA

Lymphoma Australia is the only incorporated charity dedicated to solely providing education, support, awareness and advocacy initiatives for Australians touched by lymphoma
Their history:

‘An advertisement was placed in the Gold Coast Bulletin in 2003 inviting lymphoma patients to attend an informal meeting in a park at Southport. These patients became the founding group and set up The Lymphoma Support & Research Association (LSRA) and is now known as Lymphoma Australia’.

Their message: “We will never let anyone face lymphoma/CLL alone”

‘Each day 17 Australian’s receive a Lymphoma diagnosis and if you or a loved one has been touched by Lymphoma you can call the National Lymphoma Nurse Support Line, join our closed Facebook group – Lymphoma Down Under, sign up for our e-news or request our free resources to ensure you have the information you need’.

If you, or a loved one, has been affected by a Lymphoma diagnosis, visit https://www.lymphoma.org.au/ to access vital resources and support

Information provided by https://www.lymphoma.org.au/

Blood Cancer Research WA is a not-for-profit foundation, seeking to create a WA Lymphoma Centre of Excellence (WALCRE) here in WA and run Research Trials for ALL blood cancer diseases.

We run solely on DONATIONS and fundraising

Donations enable us to have staff to support WALCRE, run Clinical Research Trials for patients suffering from ALL blood cancer, and clinically treat and manage our patients receiving treatment.

The money received in donations to date will be used to fund:
· Clinical staff members to treat & care for our patients; Haematology Doctors and Specialist Nurse
· Specific research projects in blood cancer, initiated by our own WA Haematologist’s
· Corporate Administrator/Assistant; To run operational business for the foundation

It is VITAL to keep donations coming in.

Clinical Trials give patients the best option to receive potentially life-saving treatment, which is not yet available through standard hospital treatment.
Research also provides advancements in safer, more targeted, and less harmful cancer treatment.

EVERY donation helps and all donations made through our supporter, Snowdome, is tax deductible!
Please visit BloodCancerResearch to DONATE NOW
(Select ‘WA Lymphoma Centre of Excellence’ in the Type of Donation box)

THANK YOU FOR YOUR HELP IN THE CONTINUED FIGHT AGAINST BLOOD CANCER!

Blood Cancer Research WA have proudly achieved their one year anniversary since their first official Fundraising evening which, along with the amazing funds donated by our other Supporters, enabled BCRWA to open later in 2018

(Associate Professor Chan Cheah – Founder & Director of Blood Cancer Research WA)

By enabling more clinical trials to open, Blood Cancer Research WA’s main goals are to give patients with blood cancers access to new and potentially life-saving treatments, whilst developing a WA Lymphoma Centre of Excellence to further develop research.

Across our three sites, LINEAR, Sir Charles Gairdner Hospital, and Hollywood, there are now 21 Haematology clinical trials running, with over 100 patients recruited on studies and over 60 patients actively on treatment!

Blood Cancer Research WA would like to say “THANK YOU” to all of the hard working clinical and administrative staff at BCRWA and across all of our sites who help to make this wonderful work happen, as well as our brilliant supporters: Snowdome, Lymphoma Australia,Rachael Doherty Foundation and Wildflower & COMO The Treasury Perth

WITH YOUR SUPPORT Blood Cancer Research WA can continue to make a difference in the fight against blood cancers. PLEASE DONATE NOW: https://www.bloodcancerwa.org.au/donate/

Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy

Dr Collin Chin is a Clinical Haematology Fellow at the University of Texas MD Anderson Cancer Center in Houston, Texas. He graduated in Medicine from the University of Western Australia in 2011 and completed his specialist training at Sir Charles Gairdner Hospital, Perth followed by an Aggressive Lymphoma & Chimaeric Antigen Receptor (CAR) T-cell therapy fellowship at Peter MacCallum Cancer Centre in Melbourne, Victoria.

“Our ‘Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy’ paper highlights a case of haemophagocytic lymphohistiocytosis (HLH), a rare but important complication of checkpoint inhibitor (CI) therapy which are widely used in the treatment of solid organ and haematological malignancies. We present a case report, diagnostic work-up, associated challenges in management and review the existing literature regarding HLH secondary to CI therapy.  Our findings suggest that treatment discontinuation and high-dose corticosteroid therapy without chemotherapy may be sufficient in treating HLH related to CI therapy.” (Quote by Dr Chin 31/05/19)

Collin has a specialist interest in the management of aggressive & indolent lymphoproliferative disorders, early phase clinical trials and immune effector cell (IEC) therapies including bispecific antibodies & CAR T-cell therapies. He has expertise in CAR T-cell therapy in high-risk and/or relapsed DLBCL & follicular lymphoma,
having treated the first patients to receive CAR T-cells in Australia at the Peter MacCallum Cancer Centre. Collin has also co-authored the CAR T-cell referral pathway & toxicity management guidelines at the Peter MacCallum Cancer Centre.

After completing his fellowship at the MD Anderson Cancer Center, Collin’s plan is to return to Perth and establish an immune effector cell (IEC) therapy unit for the treatment of high risk, relapsed and/or refractory lymphoproliferative disorders in Western Australia.

World Blood Cancer Day

A global awareness day dedicated to the fight against blood cancer

Have you or a loved one been affected by blood cancer?

Wear RED on 28th May and bring awareness to blood cancer and blood stem cell donation.

https://www.worldbloodcancerday.org/en/